Search

Your search keyword '"Burt, RK"' showing total 5 results
Start Over Author "Burt, RK" Publisher wiley-blackwell
5 results on '"Burt, RK"'

3. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens.

Author

Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H, Patel DD, Collier D, Heslop H, Krance R, Statkute L, Verda L, Traynor A, Kozak T, Hintzen RQ, Rose JW, Voltarelli J, Loh Y, Territo M, Cohen BA, Craig RM, Varga J, and Barr WG

Subjects
Autoimmune Diseases mortality, Humans, Immunosuppressive Agents therapeutic use, Lymphocytes drug effects, Myeloablative Agonists therapeutic use, Survival Rate, Transplantation, Autologous, Autoimmune Diseases therapy, Hematopoietic Stem Cell Transplantation methods, Randomized Controlled Trials as Topic, Transplantation Conditioning methods
Published
2006
Full Text
View/download PDF

4. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism.

Author

Burt RK, Oyama Y, Verda L, Quigley K, Brush M, Yaung K, Statkute L, Traynor A, and Barr WG

Subjects
Alemtuzumab, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm therapeutic use, Antigens, CD analysis, Antigens, Differentiation, Myelomonocytic analysis, Antirheumatic Agents therapeutic use, CD3 Complex analysis, Cyclophosphamide therapeutic use, Female, Humans, Immunosuppressive Agents therapeutic use, Middle Aged, Sialic Acid Binding Ig-like Lectin 3, Vidarabine therapeutic use, Arthritis, Rheumatoid therapy, Hematopoietic Stem Cell Transplantation, Transplantation Chimera, Vidarabine analogs & derivatives
Abstract

This report describes the first allogeneic hematopoietic stem cell transplantation (HSCT) performed for the indication of rheumatoid arthritis (RA). We used nonmyeloablative allogeneic HSCT to treat a 52-year-old woman who had treatment-refractory RA and a poor prognosis (24 swollen and 38 involved joints). She was treated with fludarabine, cyclophosphamide, CAMPATH-1H, and CD34-selected HSCT (8 million CD34+ donor cells/kg); the donor was the patient's HLA-matched, rheumatoid factor-negative sister. One year post-HSCT, the patient has had no infection except dermatomal varicella-zoster virus infection and no acute or chronic graft-versus-host disease (GVHD). Her RA has remained in remission with no immunosuppressive or immunomodulatory medications. The patient is a mixed chimera, with 55% donor T (CD3+) cells and 70% donor myeloid (CD33+) cells. This is the first published report of allogeneic HSCT performed for the indication of RA. Mixed chimerism has resulted in marked amelioration of RA, without GVHD.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results